Related News

Pictured: Memorial Sloan-Kettering logo
Memorial Sloan-Kettering Made Major Contributions to Cancer Advances in 2011

Two of the year’s top five cancer research advances cited by the American Society of Clinical Oncology were led by Memorial Sloan-Kettering investigators.

February 6, 2012
Pictured: Paul Sabbatini
Oncologist Paul Sabbatini Talks About New Strategies to Treat Ovarian Cancer

Medical oncologist Paul Sabbatini, a specialist in treating gynecologic cancers, leads a clinical research program seeking to improve treatments for ovarian cancer by harnessing the power of the immune system.

October 31, 2011
Pictured: Douglas Levine
Genomic Analysis Provides Clues about Most Common Form of Ovarian Cancer

In a large-scale genomic analysis of the most common and aggressive type of ovarian cancer, researchers from Memorial Sloan-Kettering and other centers identified genetic mutations and pathways that set the disease apart from other types of ovarian cancer and other solid tumors.

October 11, 2011
Pictured: Jedd Wolchok & Paul Chapman
Memorial Sloan-Kettering Physician-Scientists Present Significant Clinical Cancer Research Advances at ASCO Annual Meeting

In an extraordinary demonstration of excellence, five Memorial Sloan-Kettering physician-scientists were selected to participate in the press program at the 2011 American Society of Clinical Oncology annual meeting, held June 3-7 in Chicago.

July 1, 2011
First Comprehensive Analysis Of Gene Mutations In Ovarian Cancer Brings Patients One Step Closer To Personalized Medicine

According to a large-scale genomic analysis of the most common and aggressive type of ovarian cancer, researchers from Memorial Sloan- Kettering Cancer Center and other centers within The Cancer Genome Atlas (TCGA) project identified genetic mutations and pathways that distinctly set the disease apart not only from other types of ovarian cancer, but from other solid tumors as well.

June 29, 2011
Carol Aghajanian
New Drug Combination Slows Tumor Growth For Recurrent Ovarian Cancer

Bevacizumab (Avastin®) in combination with chemotherapy resulted in a clinical benefit for patients with recurrent ovarian cancer, according to a new study. Results from the phase III “OCEANS” trial were presented today by the lead author, Carol Aghajanian, MD, of Memorial Sloan-Kettering Cancer Center, at the 2011 annual meeting of the American Society of Clinical Oncology.

June 4, 2011